Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
[PMID: 6582291] PubMed record related to this compound for laboratory literature review
Like many GLP-1 receptor agonists, Byetta has been associated with weight loss or weight maintenance in some individuals
Executive Summary Quick Insight: The GLP-1 Weight Loss Drug Market is on track to more than double to USD 192 billion by 2035 , driven by explosive patient demand for injectable and oral incretin therapies, multi-indication label expansion beyond obesity into cardiovascular protection and metabolic disease management, a robust late-stage pipeline of next-generation triple agonists, and unprecedented payer engagement transforming obesity into a fully reimbursable chronic disease requiring long-term pharmacological management
By mimicking hormones that send a message to our brains that we are full up, they encourage patients to eat less
Meaning, people who go on GLP-1 drugs will lose not just fat mass but also muscle mass
US$ 21.48
US$ 24.52
US$ 26.50
US$ 24.67
US$ 25.68
US$ 21.71
US$ 27.96
